Interview with André Choulika, President, France Biotech
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
One of the special features of INNOTHERA, lies in its dual competency: pharmaceutical products and medical textiles. These two areas of expertise complement each other in a harmonious way and work towards the same end, that of treating common daily pathologies, such as venous disease. INNOTHERA’s pharmaceutical laboratory activity enables the Group to apply scientific knowledge and strict pharmaceutical processes to the medical textiles sector, thereby giving it a major advantage over its competitors.
Thanks to its human touch, INNOTHERA can concentrate its efforts on meeting assignments promptly and on achieving an excellent response rate, which is absolutely needed for managing the diversity of profiles and cultures within the group.
Currently, the INNOTHERA Group’s production is 100 % French, with exports amounting to more than 65 % of total sales, and covering more than 100 countries.
This is the price of a disciplined organisation and industrial process perfectly mastered that Innothera products in its French factories more than 20 drugs, controls 15 different dosage forms and distributes medicines in more than 100 countries.
Contact
Web: innothera.fr/en/
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
After spending 15 years at the CEA (Nuclear Energy Center), you just accepted an offer to become the General Manager of INSERM at the very moment a political reform is…
July 2008 libre acèss (free access,) for OTC market was implemented – a measure where some selected OTC products were made available over the counter within the pharmacy. Could you…
The US chooses to price its innovative drugs based on a market approach which is very different from the French system. Could you explain how the French model rewards innovative…
The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain…
What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that…
See our Cookie Privacy Policy Here
